Abstract:Background The lipoprotein(a) (Lp[a]) is a genetically determined low-density lipoprotein (LDL)-like particle. Lp(a) levels above 50mg/dl have been correlated to an increased risk of atherosclerosis and major adverse cardiovascular events. Thus, treatments designed to reduce Lp(a) levels are currently under investigation. However, it is unknown how high Lp(a) concentrations affect the control of lipid profile. Purpose The purpose of this project is to investigate how Lp(a) impacts lipid profile control in individuals with acute coronary syndromes (ACS). Methods We designed a single-center prospective registry including consecutive patients admitted for ACS. Lp(a) levels were obtained from all enrolled patients during hospitalization; lipid profile (total cholesterol (TC), LDL-cholesterol, HDL-cholesterol, triglycerides) was obtained at admission and at the 6-month follow-up (6MFU). Patients were stratified according Lp(a) concentration (low-Lp(a): Lp(a) < 50 mg/dL; high-Lp(a): Lp(a) ≥ 50 mg/dL). LDL-cholesterol (LDLcorr) levels corrected for concentration of Lp(a) were calculated as LDLcorr= LDLmeasured – 30%Lp(a). At discharge cholesterol lowering drugs were introduced or titrated as standard of care. The primary endpoint was the percentage of patients reaching target LDL and LDLcorr (<55 mg/dL) at 6MFU. The secondary endpoints were the correlations between Lp(a) levels and lipid profile, both at baseline and at 6MFU, as well as the correlation between Lp(a) levels and the total number of traditional cardiovascular risk factors in the study population. Results From February 2020 through September 2023, a total of 409 patients were included: 305 (74.6%) with Lp(a) 2 in 25.9% vs 38.1%, P=0.0244). High-Lp(a) patients showed higher level of LDL-cholesterol compared to the low-Lp(a) population both at baseline (124±52 mg/dL vs 110.4±44 mg/dL, P= 0.0263) and at 6MFU (70.5±21 vs 63.8±29, P= 0.0208) with fewer patients achieving the target LDL cholesterol levels (21.57% vs 40.13%, P=0.0184). Estimating the true LDL concentration (LDLcorr) the percentage of patients reaching target LDL cholesterol levels at FU significantly increased in the high-Lp(a) group (from 21.57% to 76.5%), with a minimal increase noticeable in the low-Lp(a) population (from 40.13% to 48.41%, p 0,1870). Conclusions In ACS population, patients with high Lp(a) concentrations have fewer traditional CV risk factors and a lower prevalence of diabetes. High-Lp(a) patients, furthermore, seem more challenging to meet LDL target at 6 month follow up, but not when the LDL values are adjusted for Lp(a).

Measurement of oxidized lipoprotein (a) in patients with acute coronary syndromes and stable coronary artery disease by 2 ELISAs: using different capture antibody against oxidized lipoprotein (a) or oxidized LDL.

[Value of Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1) and LOX-1 Mrna in Peripheral Mononuclear Cells in Early Diagnosis of Acute Coronary Syndrome].

[Correlation of Autoantibodies Against Oxidized Low Density Lipoprotein and Its Immune Complex with Coronary Artery Disease]

Elevated concentrations of oxidized lipoprotein(a) are associated with the presence and severity of acute coronary syndromes.

Development Of New Enzyme-Linked Immunosorbent Assay For Oxidized Lipoprotein(A) By Using Purified Human Oxidized Lipoprotein(A) Autoantibodies As Capture Antibody

Development of New ELISA for Oxidized Lipoprotein(a) by Using Purified Human Oxidized Lipoprotein(a) Autoantibodies As Capture Antibody

Value of serum lipoprotein(a) measurement in patients with acute coronary syndrome

A sensitive chemiluminescence imaging immunoassay for simultaneous detection of serum oxidized lipoprotein(a) and low density lipoprotein.

Relationship Between Autoantibodies Against Oxidized Low-Density Lipoprotein and High-Sensitivity C-reactive Protein in Patients with Coronary Artery Disease

Changes of Serum Oxidized Low-Density Lipoprotein in Patients with Acute and Non-Acute Coronary Artery Disease

Elevated Levels of Oxidized Low-Density Lipoprotein Correlate Positively with C-Reactive Protein in Patients with Acute Coronary Syndrome

The Level of Serum Antibody Against Oxidized Low Density Lipoprotein is Increased in Patients with Unstable Angina

Detection of IgG-bound lipoprotein(a) immune complexes in patients with coronary heart disease.

Oxidized Lipoprotein(a) Enhanced the Expression of P-selectin in Cultured Human Umbilical Vein Endothelial Cells

Development of ELISA for oxidized,malondialdehyde-modified LDL and clinical value

E0451 Combined Use of Oxidised Low Density Lipoprotein and C-reactive Protein for the Prediction of the Acute Coronary Syndrome

Oxidized Low-Density Lipoprotein Cholesterol and the Ratio in the Diagnosis and Evaluation of Therapeutic Effect in Patients with Coronary Artery Disease

[Measurement Peripheral Blood Index Related to Inflammation and Ox-Ldl, Ox-Ldlab in Patients with Coronary Heart Disease and Its Clinical Significance].

Impact of Lp(a) on lipid control in patients with acute coronary syndrome

Percutaneous coronary intervention results in increases of lipoprotein(a) and oxidized lipoprotein(a) in patients with acute coronary syndrome

Lipoprotein(a) quantified by an enzyme-linked immunosorbent assay with monoclonal antibodies